FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945740780> ?p ?o ?g. }

• W2945740780 endingPage "336.e7" @default.
• W2945740780 startingPage "328" @default.
• W2945740780 abstract "Background & AimsEosinophilic esophagitis (EoE) is caused by an immune response to specific food allergens. There are no approved therapies beyond avoidance of the allergen(s) or treatment of inflammation. Epicutaneous immunotherapy (EPIT) reduces features of eosinophilic gastrointestinal disease in mice and pigs. We performed randomized, placebo-controlled study to determine the safety and efficacy of EPIT with Viaskin milk in children with milk-induced EoE.MethodsIn a double-blind study, 20 children (4–17 years old) with milk-induced EoE were randomly assigned to groups given EPIT with Viaskin milk (n = 15) or placebo (n = 5) for 9 months during a milk-free period, followed by milk-containing diet for 2 months with EPIT. Then, subjects underwent upper endoscopy analysis, biopsies were collected, and maximum esophageal eosinophil counts were determined and was the primary endpoint. After upper endoscopy, patients were given open-label EPIT for 11 months (open-label phase). The subjects were allowed to consume milk if they had maximum values of fewer than 10 eosinophils/high-power field (eos/hpf); otherwise, they remained on a milk-free diet until the last 2 months of the open-label phase.ResultsIn the intent to treat population, there was no significant difference between the Viaskin milk group in mean eos/hpf (50.1 ± 43.97 eos/hpf) vs the placebo group (48.20 ± 56.98 eos/hpf). However, in the per-protocol population (7 patients given Viaskin milk and 2 patients given placebo), patients given Viaskin milk patients had a significantly lower mean eos/hpf count (25.57 ± 31.19) than patients given placebo (95.00 ± 63.64) (p = .038). At the end of the open-label phase, 9 of 19 evaluable subjects had mean values of fewer than 15 eos/hpf (47% response). The number of adverse events did not differ significantly between the Viaskin milk and placebo groups; there was 1 serious adverse event in the placebo group.ConclusionsIn a pilot study of pediatric patients with EoE given EPIT with Viaskin milk or placebo for 11 months, we found no significant difference between groups for the maximum eosinophil count at the end of the study. However, findings from a per-protocol analysis indicate that Viaskin milk can reduce eos/hpf. At study completion, 47% of patients who continued open-label Viaskin milk for an additional 11 months had mean values of fewer than 15 eos/hpf. ClinicalTrials.gov no: NCT02579876 Eosinophilic esophagitis (EoE) is caused by an immune response to specific food allergens. There are no approved therapies beyond avoidance of the allergen(s) or treatment of inflammation. Epicutaneous immunotherapy (EPIT) reduces features of eosinophilic gastrointestinal disease in mice and pigs. We performed randomized, placebo-controlled study to determine the safety and efficacy of EPIT with Viaskin milk in children with milk-induced EoE. In a double-blind study, 20 children (4–17 years old) with milk-induced EoE were randomly assigned to groups given EPIT with Viaskin milk (n = 15) or placebo (n = 5) for 9 months during a milk-free period, followed by milk-containing diet for 2 months with EPIT. Then, subjects underwent upper endoscopy analysis, biopsies were collected, and maximum esophageal eosinophil counts were determined and was the primary endpoint. After upper endoscopy, patients were given open-label EPIT for 11 months (open-label phase). The subjects were allowed to consume milk if they had maximum values of fewer than 10 eosinophils/high-power field (eos/hpf); otherwise, they remained on a milk-free diet until the last 2 months of the open-label phase. In the intent to treat population, there was no significant difference between the Viaskin milk group in mean eos/hpf (50.1 ± 43.97 eos/hpf) vs the placebo group (48.20 ± 56.98 eos/hpf). However, in the per-protocol population (7 patients given Viaskin milk and 2 patients given placebo), patients given Viaskin milk patients had a significantly lower mean eos/hpf count (25.57 ± 31.19) than patients given placebo (95.00 ± 63.64) (p = .038). At the end of the open-label phase, 9 of 19 evaluable subjects had mean values of fewer than 15 eos/hpf (47% response). The number of adverse events did not differ significantly between the Viaskin milk and placebo groups; there was 1 serious adverse event in the placebo group. In a pilot study of pediatric patients with EoE given EPIT with Viaskin milk or placebo for 11 months, we found no significant difference between groups for the maximum eosinophil count at the end of the study. However, findings from a per-protocol analysis indicate that Viaskin milk can reduce eos/hpf. At study completion, 47% of patients who continued open-label Viaskin milk for an additional 11 months had mean values of fewer than 15 eos/hpf. ClinicalTrials.gov no: NCT02579876" @default.
• W2945740780 created "2019-05-29" @default.
• W2945740780 creator A5007083526 @default.
• W2945740780 creator A5035926256 @default.
• W2945740780 creator A5037019785 @default.
• W2945740780 creator A5047011247 @default.
• W2945740780 creator A5059411807 @default.
• W2945740780 creator A5066272868 @default.
• W2945740780 creator A5071700754 @default.
• W2945740780 creator A5077168668 @default.
• W2945740780 creator A5088480276 @default.
• W2945740780 date "2020-02-01" @default.
• W2945740780 modified "2023-10-17" @default.
• W2945740780 title "Efficacy of Epicutaneous Immunotherapy in Children With Milk-Induced Eosinophilic Esophagitis" @default.
• W2945740780 cites W1995481725 @default.
• W2945740780 cites W2016423387 @default.
• W2945740780 cites W2043295004 @default.
• W2945740780 cites W2111316468 @default.
• W2945740780 cites W2164161262 @default.
• W2945740780 cites W2170468129 @default.
• W2945740780 cites W2284318603 @default.
• W2945740780 cites W2555473786 @default.
• W2945740780 cites W2741734981 @default.
• W2945740780 cites W2757586023 @default.
• W2945740780 cites W2768781972 @default.
• W2945740780 cites W2779886382 @default.
• W2945740780 cites W2786681680 @default.
• W2945740780 cites W2800804398 @default.
• W2945740780 cites W2883311417 @default.
• W2945740780 cites W2885015158 @default.
• W2945740780 cites W4239894904 @default.
• W2945740780 doi "https://doi.org/10.1016/j.cgh.2019.05.014" @default.
• W2945740780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31100455" @default.
• W2945740780 hasPublicationYear "2020" @default.
• W2945740780 type Work @default.
• W2945740780 sameAs 2945740780 @default.
• W2945740780 citedByCount "28" @default.
• W2945740780 countsByYear W29457407802019 @default.
• W2945740780 countsByYear W29457407802020 @default.
• W2945740780 countsByYear W29457407802021 @default.
• W2945740780 countsByYear W29457407802022 @default.
• W2945740780 countsByYear W29457407802023 @default.
• W2945740780 crossrefType "journal-article" @default.
• W2945740780 hasAuthorship W2945740780A5007083526 @default.
• W2945740780 hasAuthorship W2945740780A5035926256 @default.
• W2945740780 hasAuthorship W2945740780A5037019785 @default.
• W2945740780 hasAuthorship W2945740780A5047011247 @default.
• W2945740780 hasAuthorship W2945740780A5059411807 @default.
• W2945740780 hasAuthorship W2945740780A5066272868 @default.
• W2945740780 hasAuthorship W2945740780A5071700754 @default.
• W2945740780 hasAuthorship W2945740780A5077168668 @default.
• W2945740780 hasAuthorship W2945740780A5088480276 @default.
• W2945740780 hasBestOaLocation W29457407801 @default.
• W2945740780 hasConcept C126322002 @default.
• W2945740780 hasConcept C142724271 @default.
• W2945740780 hasConcept C168563851 @default.
• W2945740780 hasConcept C203014093 @default.
• W2945740780 hasConcept C203092338 @default.
• W2945740780 hasConcept C204787440 @default.
• W2945740780 hasConcept C207480886 @default.
• W2945740780 hasConcept C27081682 @default.
• W2945740780 hasConcept C2776042228 @default.
• W2945740780 hasConcept C2777037409 @default.
• W2945740780 hasConcept C2779134260 @default.
• W2945740780 hasConcept C2781065132 @default.
• W2945740780 hasConcept C2908647359 @default.
• W2945740780 hasConcept C71924100 @default.
• W2945740780 hasConcept C90924648 @default.
• W2945740780 hasConcept C99454951 @default.
• W2945740780 hasConceptScore W2945740780C126322002 @default.
• W2945740780 hasConceptScore W2945740780C142724271 @default.
• W2945740780 hasConceptScore W2945740780C168563851 @default.
• W2945740780 hasConceptScore W2945740780C203014093 @default.
• W2945740780 hasConceptScore W2945740780C203092338 @default.
• W2945740780 hasConceptScore W2945740780C204787440 @default.
• W2945740780 hasConceptScore W2945740780C207480886 @default.
• W2945740780 hasConceptScore W2945740780C27081682 @default.
• W2945740780 hasConceptScore W2945740780C2776042228 @default.
• W2945740780 hasConceptScore W2945740780C2777037409 @default.
• W2945740780 hasConceptScore W2945740780C2779134260 @default.
• W2945740780 hasConceptScore W2945740780C2781065132 @default.
• W2945740780 hasConceptScore W2945740780C2908647359 @default.
• W2945740780 hasConceptScore W2945740780C71924100 @default.
• W2945740780 hasConceptScore W2945740780C90924648 @default.
• W2945740780 hasConceptScore W2945740780C99454951 @default.
• W2945740780 hasFunder F4320309099 @default.
• W2945740780 hasFunder F4320327303 @default.
• W2945740780 hasIssue "2" @default.
• W2945740780 hasLocation W29457407801 @default.
• W2945740780 hasOpenAccess W2945740780 @default.
• W2945740780 hasPrimaryLocation W29457407801 @default.
• W2945740780 hasRelatedWork W1599977015 @default.
• W2945740780 hasRelatedWork W1763325369 @default.
• W2945740780 hasRelatedWork W1968069454 @default.
• W2945740780 hasRelatedWork W1981755041 @default.
• W2945740780 hasRelatedWork W2082314345 @default.
• W2945740780 hasRelatedWork W2105720921 @default.
• W2945740780 hasRelatedWork W2333054596 @default.

• next